Evidence map›Paper›PMID 35728739›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2022

Photothermal immunotherapy of melanoma using TLR-7 agonist laden tobacco mosaic virus with polydopamine coat.

Christian Isalomboto Nkanga, Oscar A Ortega-Rivera, Nicole F Steinmetz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christian Isalomboto NkangaDepartment of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States.
Oscar A Ortega-RiveraDepartment of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States; Center for Nano-ImmunoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States.
Nicole F SteinmetzDepartment of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States; Department of Bioengineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States; Department of Radiology, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States; Center for Nano-ImmunoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States; Moores Cancer Center, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States; Institute for Materials Discovery and Design, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, United States. Electronic address: nsteinmetz@ucsd.edu.
University of California, San Diego · US

Funding

Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging.R01CA202814 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STEINMETZ, NICOLE FRANZISKA · 2016 to 2020
$2.0M
NCI NIH HHS R01 CA202814
6 · The paper itself

Abstract

Photothermal therapy (PTT) is a promising cancer treatment that debulks tumors locally while priming immune responses. However, PTT as a standalone treatment approach often has limited systemic efficacy, motivating the development of synergistic combination approaches. Toward this goal, herein, the tobacco mosaic virus (TMV) was loaded with a small molecule immunomodulator, toll-like receptor 7 agonist (1V209), and its surface was coated with photothermal biopolymer polydopamine (PDA). The resulting 1V209-laden and PDA-coated TMV was used to treat B16F10 dermal melanoma in C57BL/6 mice. 1V209-TMV-PDA was intratumorally injected and irradiated using an 808-nm near infrared laser. 60 % of the mice receiving PTT with intratumoral 1V209-TMV-PDA + laser remained alive at the end point - in contrast to only 20 % survivors were observed in the control group. Immunological analysis indicates systemic anti-tumor immunity being induced by the combination therapy with a greater number of tumor-specific T cells (as determined by a splenocyte assay). This study highlights the potential of TMV versatility as a multifunctional nano-platform for combined PTT-immunotherapy.

Indexed as

MelanomaNanoparticlesTobacco Mosaic VirusAdjuvants, ImmunologicAnimalsCell Line, TumorImmunotherapyIndolesMiceMice, Inbred C57BLPhototherapyPolymersToll-Like Receptor 7Adjuvants, ImmunologicIndolespolydopaminePolymersToll-Like Receptor 7Anti-tumor immunotherapyMelanomaNanoparticlesPhotothermal therapyPolydopamineTLR-7 agonistTobacco mosaic virus

Identifiers

PMID35728739
PMCPMC10530638
OpenAlexW4283080058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.